肿瘤细胞治疗研究
ALL SOURCES
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
这是一项 II 期注册临床试验，评估细胞治疗用于急性淋巴细胞白血病、淋巴瘤的疗效与安全性。当前状态：招募中。计划入组 125 例。试验地点：美国 · 杜阿尔特、洛杉矶、丹佛、华盛顿特区（共 18 个中心）。登记号：NCT06514794。
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia
In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicity.
CAR T cells: the missing piece needed to improve outcomes for children with cancer?
Donor-derived CD7 CAR-T in T-ALL/LBL: promise and pitfalls.
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.
CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
这是一项 I 期注册临床试验，评估异体 CAR-T 细胞治疗急性淋巴细胞白血病的安全性、可行性及初步疗效。当前状态：招募中。计划入组 33 例。试验地点：美国 · 费城（共 1 个中心）。登记号：NCT06934382。
Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
